Exact Sciences has launched Oncodetect, a new test designed to detect molecular residual disease (MRD) across multiple solid tumors, the company announced today.

“Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions,” Exact Sciences Executive Vice President and General Manager of Precision Oncology Brian Baranick said in a statement. “Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.”

According to a release, the test tracks up to 200 tumor-specific variants and provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process.

Exact Sciences is actively working with Medicare to secure reimbursement for the test.